PT  - JOURNAL ARTICLE
AU  - Y. MAURICE MORILLON II
AU  - ARIANA SABZEVARI
AU  - JEFFREY SCHLOM
AU  - JOHN W. GREINER
TI  - The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents
AID  - 10.21873/anticanres.14540
DP  - 2020 Oct 01
TA  - Anticancer Research
PG  - 5329--5341
VI  - 40
IP  - 10
4099  - http://ar.iiarjournals.org/content/40/10/5329.short
4100  - http://ar.iiarjournals.org/content/40/10/5329.full
SO  - Anticancer Res2020 Oct 01; 40
AB  - Investigation of the efficacy and mechanisms of human immuno-oncology agents has been hampered due to species-specific differences when utilizing preclinical mouse models. Peripheral blood mononuclear cell (PBMC) humanized mice provide a platform for investigating the modulation of the human immune-mediated antitumor response while circumventing the limitations of syngeneic model systems. Use of humanized mice has been stymied by model-specific limitations, some of which include the development of graft versus host disease, technical difficulty and cost associated with each humanized animal, and insufficient engraftment of some human immune subsets. Recent advances have addressed many of these limitations from which have emerged humanized models that are more clinically relevant. This review characterizes the expanded usage, advantages and limitations of humanized mice and provides insights into the development of the next generation of murine humanized models to further inform clinical applications of cancer immunotherapeutic agents.